Daiichi Sankyo Expands Business In Turkey, India
This article was originally published in PharmAsia News
Executive Summary
Daiichi Sankyo is expanding operations in India and Turkey as it builds its sales networks. The Japanese drug maker said the first expansion is in Turkey with its Daiichi Sankyo Ilac Ticaret wholly owned subsidiary. The Turkey unit already is operating, with 20 medical representatives to market Daiichi's Evista (raloxifene hydrochloride) osteoporosis treatment. The India entry is expected to begin in June with Daiichi's promotion agreement with GlaxoSmithKline of the U.K. (Click here for more - may require a subscription
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.